期刊文献+

龟分枝杆菌和脓肿分枝杆菌药物敏感性分析及E试验法应用评价 被引量:3

Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing
原文传递
导出
摘要 目的分析深圳地区龟分枝杆菌和脓肿分枝杆菌耐药谱,评价E试验法检测龟分枝杆菌和脓肿分枝杆菌药物敏感性的临床适用性。方法用Geno Type Mycobacterium CM分枝杆菌菌种鉴定系统筛选16株龟分枝杆菌临床菌株、20株脓肿分枝杆菌临床菌株,分别用微量肉汤稀释法和E试验法检测其对阿米卡星、头孢西丁、环丙沙星、克拉霉素、多西环素、亚胺培南、利奈唑胺、磺胺甲嗯唑/甲氧苄啶和妥布霉素9种抗生素的MIC,以微量肉汤稀释法为标准,评价E试验法的MIC值符合率和MIC解释的一致率。两组间率的比较采用,检验。结果龟分枝杆菌和脓肿分枝杆菌对阿米卡星和头孢西丁均敏感(36/36),对克拉霉素的耐药率较低(1/36),对环丙沙星、多西环素、亚胺培南和磺胺甲嗯唑/甲氧苄啶的耐药率较高(29/36)。龟分枝杆菌和脓肿分枝杆菌对利奈唑胺的耐药例数分别为2/16和12/20,对妥布霉素的耐药例数分别为7/16和16/20。E试验法检测9种抗生素的MIC值分布与微量肉汤稀释法MIC值分布的总体符合率为46%(149/324),MIC解释一致率最高的分别为阿米卡星、克拉霉素、多西环素和亚胺培南(35/36),其次为磺胺甲嗯唑/甲氧苄啶(34/36),2例(2/36)解释结果有重大误差;一致率较高的为环丙沙星(31/36)和妥布霉素(26/36);一致率最低的为头孢西丁和利奈唑胺(14/36),易导致MIC解释出现假阳性。结论阿米卡星、头孢西丁和克拉霉素对龟分枝杆菌和脓肿分枝杆菌有良好的体外抗菌作用,利奈唑胺、妥布霉素对部分龟分枝杆菌有良好的体外抗菌作用。除头孢西丁和利奈唑胺外,阿米卡星、克拉霉素、多西环素、环丙沙星和妥布霉素均适用E试验法检测龟分枝杆菌和脓肿分枝杆菌的体外药物敏感性,需慎重采用E试验法检测磺胺甲嗯唑/甲氧苄啶的药物敏感性。 Objective To study the drug resistance profile of Mycobacterium (M.) chelonae and M. abscessus and to evaluate the clinical application of Etest (epsilometer test ) for susceptibility testing. Methods Twenty clinical isolates of M. abscessus and 16 clinical isolates of M. chelonae from clinical specimens were collected. Strain identification was carried out by GenoType Mycobacterium CM assay (Hain Lifescience, Germany). The accuracy was evaluated by comparing Etest results to those obtained by broth microdilution. Thirty-six isolates were tested against amikacin, cefnxitin, ciprofloxacin, clarithromycin, doxyeycline, imipenem, linezolid, sulfamethoxazole and tobramycin. The agreement among MICs and interpretive category was evaluated. Chi-squared test was used to compare observed frequency of each of the 2 examples. Results All of the isolates (36/36) were sensitive to amikacin and cefoxitin, and only l isolate (1/36) was resistant to clarithromycin, but more isolates (29/36) were resistant to ciprofloxacin, doxycycline, imipenem and sulfamethoxazole. For M. chelonae, only 2/16 were resistant to linezolid, and 7/16 resistant to tobramycin. For M. abscessus, more than 12/20 were resistant to linezolid and 16/20 resistant to tobramycin. The agreement between broth microdilution M^Cs and Etest MICs for 9 drugs was 149/324. With amikacin, clarithromycin, doxycycline and imipenem, the agreement for interpretive category was excellent( 35/36 ) , followed by sulfamethoxazole( 34/36 ) , which corresponded to rarely very major error of 2/36. With ciprofloxacin and tobramycin, agreement for interpretive category was 31/36 and 26/36. With cefoxitin and linezolid, the agreement of Etest MICs was the lowest(14/36) , resulting in the resistant category. Conclusions Isolates of M. chelortae and M. abscessus exhibit far more susceptibility to amikacin, cefoxitin and clarithromyein than any other antimicrobial agents. Linezolid and tobramyein showed sensitivity to some isolates of M. chelortae. It is suitable for the Etest method as a simple reliable method for the drug susceptibility of amikacin, ciprofloxacin, clarithromyein, doxycyeline, imipenem, and tobramycin except to cefoxitin and linezolid. The Etest method of determining sulfamethoxazole susceptibility should be careful.
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2013年第8期567-571,共5页 Chinese Journal of Tuberculosis and Respiratory Diseases
基金 国家“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项课题(2012ZX10004-903) 深圳市科技计划项目(JCYJ20130402154801094)
关键词 分枝杆菌 龟亚科 分枝杆菌 脓肿 微生物敏感性试验 Mycobacterium chelonae Mycobacterium abscessus Microbial sensitivity tests
  • 相关文献

参考文献12

  • 1Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontubereulous myeobaeterial diseases. Am J Respir Crit Care Med, 2007, 175:367-416.
  • 2Broda A, Jebbari H, Beaton K, et al. Comparative drug resistance of Mycobacterium abscessus and M. ehelonae isolates from patients with and without cystic fibrosis in the United Kingdom. J Clin Microbiol, 2013, 51:217-223.
  • 3Biehle JR, Cavalieri SJ, Saubolle MA, et al. Evaluation of Etest for susceptibility testing of rapidly growing mycobacteria. J Clin Microbiol, 1995, 33:1760-1764.
  • 4Woods GL, Bergmann JS, Witebsky FG, et al. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol, 1999, 37 : 1676-1682.
  • 5Biedenbach DJ, Jones RN. Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin : investigation using 510 (k) review criteria, recommended by the Food and Drug Administration. J Clin M icrobiol, 1996, 34:3214- 3217.
  • 6Clinical and Laboratory Standards Institude. Susceptibility testing of mycobacteria, nocardia and other aerobic actinomycetes; approved standard. M24-A. Wayne:CLSI, 2003.
  • 7Clinical and Laboratory Standards Institude. Performance standards for antimicrobial susceptibility testing; twenty informational supplement. M100-S20. Wayne:CLSI, 2010.
  • 8Woods GL, Bergmann JS, Witebsky FG, et al. Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelortae, and Mycobacterium fortuitum. J Clin Microbiol, 2000, 38:656-661.
  • 9Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm( 41 ) and rrl sequencing. Antimicrob Agents Chemother, 2011, 55:775-781.
  • 10Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev, 2012. 25,545-582.

同被引文献22

  • 1Le(a)o SC,Viana-Niero C,Matsumoto CK,et al.Epidemic of surgical-site infections by a single clone of rapidly growing mycobacteria in Brazil[J].Future Microbiol,2010,5:971-980.
  • 2Adékambi T,Reynaud-Gaubert M,Greub G,et al.Amoebal coculture of " Mycobacterium massiliense " sp.nov.from the sputum of a patient with hemoptoic pneumonia.J Clin Microbiol,2004,42:5493-5501.
  • 3Macheras E,Roux AL,Bastian S,et al.Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus(sensu lato) strains[J].J Clin Microbiol,2011,49:491-499.
  • 4Macheras E,Roux AL,Ripoll F,et al.Inaccuracy of single-target sequencing for discriminating species of the Mycobacterium abscessus group[J].J Clin Microbiol,2009,47:2596-2600.
  • 5Nash KA,Brown-Elliott BA,Wallace RJ Jr.A novel gene,erm(41),confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae[J].Antimicrob Agents Chemother,2009,53:1367-1376.
  • 6Bastian S,Veziris N,Roux AL,et al.Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing[J].Antimicrob Agents Chemother,2011,55:775-781.
  • 7Telenti A,Marchesi F,Balz M,et al.Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis[J].J Clin Microbiol,1993,31:175-178.
  • 8Adékambi T,Colson P,Drancourt M.rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria[J].J Clin Microbiol,2003,41:5699-5708.
  • 9Clinical and Laboratory Standards Institude.Susceptibility testing of mycobacteria,nocardia and other aerobic actinomycetes; approved standard.M24-A[S].Wayne:CLSI,2003.
  • 10Viana-Niero C,Lima KV,Lopes ML,et al.Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures[J].J Clin Microbiol,2008,46:850-855.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部